408 related articles for article (PubMed ID: 26866475)
1. Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer.
Park S; Yoon JH; Sohn J; Park HS; Moon HJ; Kim MJ; Kim EK; Kim SI; Park BW
PLoS One; 2016; 11(2):e0149347. PubMed ID: 26866475
[TBL] [Abstract][Full Text] [Related]
2. The percentage of residual DCIS in patients diagnosed with primary invasive breast cancer treated with neoadjuvant systemic therapy: A nationwide retrospective study.
Ploumen RAW; Keymeulen KBMI; Kooreman LFS; van Kuijk SMJ; Siesling S; Smidt ML; van Nijnatten TJA
Eur J Surg Oncol; 2022 Jan; 48(1):60-66. PubMed ID: 34756527
[TBL] [Abstract][Full Text] [Related]
3. Residual Mammographic Microcalcifications and Enhancing Lesions on MRI After Neoadjuvant Systemic Chemotherapy for Locally Advanced Breast Cancer: Correlation with Histopathologic Residual Tumor Size.
Kim YS; Chang JM; Moon HG; Lee J; Shin SU; Moon WK
Ann Surg Oncol; 2016 Apr; 23(4):1135-42. PubMed ID: 26628432
[TBL] [Abstract][Full Text] [Related]
4. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
[TBL] [Abstract][Full Text] [Related]
5. Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?
Schaefgen B; Mati M; Sinn HP; Golatta M; Stieber A; Rauch G; Hennigs A; Richter H; Domschke C; Schuetz F; Sohn C; Schneeweiss A; Heil J
Ann Surg Oncol; 2016 Mar; 23(3):789-95. PubMed ID: 26467456
[TBL] [Abstract][Full Text] [Related]
6. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
[TBL] [Abstract][Full Text] [Related]
7. MRI evaluation of residual breast cancer after neoadjuvant chemotherapy: influence of patient, tumor and chemotherapy characteristics on the correlation with pathological response.
Diguisto C; Ouldamer L; Arbion F; Vildé A; Body G
Anticancer Res; 2015 Jan; 35(1):581-5. PubMed ID: 25550606
[TBL] [Abstract][Full Text] [Related]
8. Imaging findings for response evaluation of ductal carcinoma in situ in breast cancer patients treated with neoadjuvant systemic therapy: a systematic review and meta-analysis.
Ploumen RAW; de Mooij CM; Gommers S; Keymeulen KBMI; Smidt ML; van Nijnatten TJA
Eur Radiol; 2023 Aug; 33(8):5423-5435. PubMed ID: 37020070
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Residual Disease With Molecular Breast Imaging in Patients Undergoing Neoadjuvant Therapy: Association With Molecular Subtypes.
Menes TS; Golan O; Vainer G; Lerman H; Schneebaum S; Klausner J; Even-Sapir E
Clin Breast Cancer; 2016 Oct; 16(5):389-395. PubMed ID: 27282845
[TBL] [Abstract][Full Text] [Related]
10. Complete response on MR imaging after neoadjuvant chemotherapy in breast cancer patients: Factors of radiologic-pathologic discordance.
Choi WJ; Kim HH; Cha JH; Shin HJ; Chae EY; Yoon GY
Eur J Radiol; 2019 Sep; 118():114-121. PubMed ID: 31439230
[TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?
Okamoto S; Yamada T; Kanemaki Y; Kojima Y; Tsugawa K; Nakajima Y
Breast Cancer; 2016 Sep; 23(5):789-96. PubMed ID: 26437647
[TBL] [Abstract][Full Text] [Related]
12. Magnetic Resonance Imaging Combined With Second-look Ultrasonography in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Primary Breast Cancer Patients.
Hayashi N; Tsunoda H; Namura M; Ochi T; Suzuki K; Yamauchi H; Nakamura S
Clin Breast Cancer; 2019 Feb; 19(1):71-77. PubMed ID: 30206035
[TBL] [Abstract][Full Text] [Related]
13. Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients.
Baumgartner A; Tausch C; Hosch S; Papassotiropoulos B; Varga Z; Rageth C; Baege A
Breast; 2018 Jun; 39():19-23. PubMed ID: 29518677
[TBL] [Abstract][Full Text] [Related]
14. Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer by combining magnetic resonance imaging and core needle biopsy.
Narui K; Ishikawa T; Oba MS; Hasegawa Y; Kaise H; Kawate T; Yamada A; Yamada K; Suzuki Y; Niikura N; Kohno N; Kimoto T; Sugae S; Kosaka Y; Miyashita M; Okamura T; Shimizu D; Tanino H; Tanabe M; Morita S; Endo I; Tokuda Y
Surg Oncol; 2020 Dec; 35():447-452. PubMed ID: 33045629
[TBL] [Abstract][Full Text] [Related]
15. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.
Cho JH; Park JM; Park HS; Park S; Kim SI; Park BW
J Surg Oncol; 2013 Dec; 108(8):531-6. PubMed ID: 24115142
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of axillary nodal imaging by magnetic resonance imaging based on breast cancer subtype after neoadjuvant chemotherapy.
Steiman J; Soran A; McAuliffe P; Diego E; Bonaventura M; Johnson R; Ahrendt G; McGuire K
J Surg Res; 2016 Jul; 204(1):237-41. PubMed ID: 27451892
[TBL] [Abstract][Full Text] [Related]
17. Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?
Heil J; Schaefgen B; Sinn P; Richter H; Harcos A; Gomez C; Stieber A; Hennigs A; Rauch G; Schuetz F; Sohn C; Schneeweiss A; Golatta M
Eur J Cancer; 2016 Dec; 69():142-150. PubMed ID: 27821317
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy.
Marinovich ML; Houssami N; Macaskill P; Sardanelli F; Irwig L; Mamounas EP; von Minckwitz G; Brennan ME; Ciatto S
J Natl Cancer Inst; 2013 Mar; 105(5):321-33. PubMed ID: 23297042
[TBL] [Abstract][Full Text] [Related]
19. Comparing Accuracy of Mammography and Magnetic Resonance Imaging for Residual Calcified Lesions in Breast Cancer Patients Undergoing Neoadjuvant Systemic Therapy.
Um E; Kang JW; Lee S; Kim HJ; Yoon TI; Sohn G; Chung IY; Kim J; Lee JW; Son BH; Ahn SH; Ko BS
Clin Breast Cancer; 2018 Oct; 18(5):e1087-e1091. PubMed ID: 29703689
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
von Minckwitz G; Schneeweiss A; Loibl S; Salat C; Denkert C; Rezai M; Blohmer JU; Jackisch C; Paepke S; Gerber B; Zahm DM; Kümmel S; Eidtmann H; Klare P; Huober J; Costa S; Tesch H; Hanusch C; Hilfrich J; Khandan F; Fasching PA; Sinn BV; Engels K; Mehta K; Nekljudova V; Untch M
Lancet Oncol; 2014 Jun; 15(7):747-56. PubMed ID: 24794243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]